Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Assess the Efficacy and Safety of AX-8 in Patients With Chronic Cough

Next Previous
X
Search
Trial Profile

A Phase 2 Study to Assess the Efficacy and Safety of AX-8 in Patients With Chronic Cough

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AX-8 (Primary)
  • Indications Cough
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Axalbion

    • Most Recent Events

    • 27 Aug 2024 According to an Axalbion media release, company announced that the first patient has been dosed in the second part of this study.
    • 11 Jul 2024 Planned number of patients changed from 50 to 100.
    • 11 Jul 2024 Number of treatment arms are increased from 2 to 4 by the addition of 2 more arms for part-2 of the study. Planned enrollment is increased.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top